Cargando…
Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor
BACKGROUND: Androgen ablation is one of the viable therapeutic options for patients with primary hormone (androgen)-dependent prostate cancer. However, an antibiotic brefeldin A (BFA) has been shown to exhibit the growth inhibitory effect on human cancer cells. We thus investigated if BFA might inhi...
Autores principales: | Rajamahanty, Srinivas, Alonzo, Catherine, Aynehchi, Shahrad, Choudhury, Muhammad, Konno, Sensuke |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843609/ https://www.ncbi.nlm.nih.gov/pubmed/20102617 http://dx.doi.org/10.1186/1423-0127-17-5 |
Ejemplares similares
-
Possible immunotherapeutic potentiation with D-Fraction in prostate cancer cells
por: Pyo, Paul, et al.
Publicado: (2008) -
Possible disease remission in patient with invasive bladder cancer with D-fraction regimen
por: Rajamahanty, Srinivas, et al.
Publicado: (2009) -
Dominant-Negative Androgen Receptor Inhibition of Intracrine Androgen-Dependent Growth of Castration-Recurrent Prostate Cancer
por: Titus, Mark A., et al.
Publicado: (2012) -
Zinc Inhibits Expression of Androgen Receptor to Suppress Growth of Prostate Cancer Cells
por: To, Phuong Kim, et al.
Publicado: (2018) -
Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells.
por: Sherwood, E. R., et al.
Publicado: (1998)